Jack Brennan is a Principal in the New York* office of Fish & Richardson. His practice emphasizes patent prosecution, opinions, due diligence, and client counseling in the fields of biotechnology and pharmaceuticals. Dr. Brennan's doctoral research involved identification and characterization of cell surface receptors used by natural killer cells to identify target cells.
*Not admitted to practice in New York – practice in New York limited to federal courts and agencies listed below or otherwise authorized by law.
"Timing of PTO Disclosures – A Trap for the Unwary," Ahmed Davis, Jack Brennan, Pharmaceutical Compliance Monitor (December 20, 2013).
"Adjusting the life of a US patent due to Patent Office delay," Cherylyn Esoy Mizzo, Jack Brennan, John B. Pegram, Industrial Biotechnology (February 2010), 6(1): 18-21.
Brennan "A state based right to physician assisted suicide," B.U.L. Rev. 79:231 (1999).
Brennan et al. "Heterogeneity among Ly-49C natural killer (NK) cells: Characterization of highly related receptors with differing functions and expression patterns," J. Exp. Med. 184:2085 (1996).
Brennan et al. "Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions," J. Exp. Med. 183:1553 (1996).
Brennan et al. "Carbohydrate recognition by a natural killer cell receptor, Ly-49C," J. Biol. Chem. 270:9691 (1995).
Brennan et al. "Expression of different members of the Ly-49 gene family defines distinct natural killer cell subsets and cell adhesion properties," J. Exp. Med. 180:2287 (1994).